Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23666572 | 0.81 | — | — | |
| SCHEMBL20988831 | 0.74 | DRD2 (0.35) | CHRM3 | |
| SCHEMBL19277014 | 0.74 | CHRM3 (0.37) | CHRM3 | |
| SCHEMBL21757273 | 0.72 | CHRM3 (0.30) | CHRM3 | |
| SCHEMBL12694277 | 0.72 | NPC1 (0.38) | — | |
| SCHEMBL19352917 | 0.72 | CNR2 (0.39) | — | |
| SCHEMBL22096305 | 0.70 | — | — | |
| SCHEMBL20415972 | 0.70 | MAPT (0.38) | — | |
| SCHEMBL23849225 | 0.69 | CNR2 (0.47) | — | |
| SCHEMBL20098929 | 0.69 | CNR2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-10278942-B2 | Compositions for use in treating pulmonary arterial hypertension | PELOTON THERAPEUTICS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180177754-A1 | COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION | PELOTON THERAPEUTICS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | PELOTON THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | CHRM3 3360/4885 |
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | MGMT, NEFM, TUBB3 | CHRM3 3811/4885 |
| US-10278942-B2 | Compositions for use in treating pulmonary arterial hypertension | MYLK, TNNI3, PDE2A | CHRM3 183/4885 |
| US-20180177754-A1 | COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION | MYLK, TNNI3, PDE2A | CHRM3 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.